These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32720297)

  • 1. Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in Pharmacovigilance.
    Lee I; Jokinen JD; Crawford SY; Calip GS; Kilpatrick RD; Lee TA
    Ther Innov Regul Sci; 2021 Jan; 55(1):142-151. PubMed ID: 32720297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance.
    Lee I; Lee TA; Crawford SY; Kilpatrick RD; Calip GS; Jokinen JD
    Expert Opin Drug Saf; 2020 Oct; 19(10):1357-1366. PubMed ID: 32662668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade.
    Tsuchiya M; Obara T; Miyazaki M; Noda A; Takamura C; Mano N
    Int J Clin Pharm; 2020 Apr; 42(2):728-736. PubMed ID: 32020439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues.
    Bergvall T; Norén GN; Lindquist M
    Drug Saf; 2014 Jan; 37(1):65-77. PubMed ID: 24343765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data-Driven Identification of Factors That Influence the Quality of Adverse Event Reports: 15-Year Interpretable Machine Learning and Time-Series Analyses of VigiBase and QUEST.
    Choo SM; Sartori D; Lee SC; Yang HC; Syed-Abdul S
    JMIR Med Inform; 2024 Apr; 12():e49643. PubMed ID: 38568722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
    Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
    Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The completeness of adverse drug reaction reports in South Africa: An analysis in VigiBase®.
    Matlala MF; Lubbe MS; Steyn H
    Afr J Prim Health Care Fam Med; 2023 Jan; 15(1):e1-e9. PubMed ID: 36744452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain-differences between regional pharmacovigilance centres and pharmaceutical industry.
    Fernandez-Fernandez C; Lázaro-Bengoa E; Fernández-Antón E; Quiroga-González L; Montero Corominas D
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1175-1181. PubMed ID: 32447435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis.
    Araujo AGS; Lucchetta RC; Tonin FS; Pontarolo R; Borba HHL; Wiens A
    Expert Opin Drug Saf; 2021 Jun; 20(6):735-740. PubMed ID: 33641547
    [No Abstract]   [Full Text] [Related]  

  • 10. Industry Assessment of the Contribution of Patient Support Programs, Market Research Programs, and Social Media to Patient Safety.
    Jokinen J; Bertin D; Donzanti B; Hormbrey J; Simmons V; Li H; Dharmani C; Kracht K; Hilzinger TS; Verdru P
    Ther Innov Regul Sci; 2019 Nov; 53(6):736-745. PubMed ID: 31684774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse event classification and signal detection of data from the customer service and pharmacovigilance of a multinational veterinary pharmaceutical company.
    Marcon DS; Queiroz MR; Baquero OS
    Prev Vet Med; 2022 Sep; 206():105704. PubMed ID: 35850073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in Pharmacovigilance.
    Vemula GK; Badale P; Mavrogenis P; Lalande-Luesink I; Borkowski M; Lewis DJ
    Adv Ther; 2024 Jan; 41(1):82-91. PubMed ID: 37919600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
    Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
    Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria.
    Elemuwa UG; Bitrus F; Oreagba IA; Osakwe AI; Abiodun AS; Onu K; Abubakar A; Faniyi AE; Etuk V; Yuah D; Momodu R; Adeyeye CM
    Pharmaceut Med; 2024 May; 38(3):251-259. PubMed ID: 38705932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Completeness of pharmacovigilance reporting in general medicine in France.].
    Humbert X; Jacquot J; Alexandre J; Sassier M; Robin N; Pageot C; Kheloufi F; Joyau C; Coquerel A; Durrieu G; Fedrizzi S
    Sante Publique; 2019; Vol. 31(4):561-566. PubMed ID: 31959257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential completeness of spontaneous adverse event reports among hospitals/clinics, pharmacies, consumers, and pharmaceutical companies in South Korea.
    Oh IS; Baek YH; Kim HJ; Lee M; Shin JY
    PLoS One; 2019; 14(2):e0212336. PubMed ID: 30763386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timeline representation of clinical data: usability and added value for pharmacovigilance.
    Ledieu T; Bouzillé G; Thiessard F; Berquet K; Van Hille P; Renault E; Polard E; Cuggia M
    BMC Med Inform Decis Mak; 2018 Oct; 18(1):86. PubMed ID: 30340483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of factors associated with completeness of spontaneous adverse event reporting in the United States: A comparison between consumer reports and healthcare professional reports.
    Toki T; Ono S
    J Clin Pharm Ther; 2020 Jun; 45(3):462-469. PubMed ID: 31765498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of Signals of Designated Medical Events and Non-designated Medical Events: Results from a Scoping Review.
    Sartori D; Aronson JK; Erlanson N; Norén GN; Onakpoya IJ
    Drug Saf; 2024 May; 47(5):475-485. PubMed ID: 38401041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.